Conference Summary
It is widely recognized that protein aggregation and protein misfolding result in many neurodegenerative diseases worldwide. These include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, dementia with Lewy bodies, frontotemporal diseases, systemic amyloidosis, prion diseases, and multiple system atrophy. Recent successes in the treatment of ALS-SOD1 using antisense oligonucleotides offer promise.

However, while the latest FDA-approved drugs for Alzheimer’s Disease (AD) modestly slow cognitive and functional decline in early-stage patients by targeting amyloid plaques, these drugs are far from being efficacious, disease-modifying drugs, and come with serious potential risks. 

A better understanding of protein aggregation mechanisms will provide a framework for the discussion about the development of therapies against these devastating and often fatal diseases. This conference will bring together researchers to discuss the latest advances in protein aggregation, protein misfolding, and emerging therapeutic strategies to advance the field.